Krystal Biotech (KRYS) Director Julian S. Gangolli Receives Awards

What Happened

• Julian S. Gangolli, a member of Krystal Biotech’s Board of Directors, received two awards on September 14, 2026: 1,187 derivative stock option units (reported at $0.00) and 471 restricted stock units (RSUs) (reported at $0.00). These are grants (compensation awards), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-09-14; Form 4 filed 2026-09-16 (timely within the SEC reporting window).
• Awards reported at $0.00 per unit (common for grant reporting); total cash value at grant was not stated.
• 1,187 units: stock options that vest in full on September 14, 2027, subject to continued board service and earlier vesting under the company’s Non‑Employee Director Compensation Policy (Footnote F1).
• 471 units: RSUs (each representing a contingent right to one share) that vest in full on September 14, 2027, subject to the same service/earlier‑vesting terms (Footnotes F2–F3).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No 10b5‑1 plan, tax‑withholding sale, or late‑filing flag was indicated in the supplied details.

Context

• These awards are routine director compensation (derivative grants tied to continued service) rather than open‑market buys or sales; they do not by themselves indicate a personal purchase or sale decision.
• For retail investors: awards like RSUs and director option grants are commonly used to align board members’ interests with shareholders and typically vest over time contingent on continued service.